Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Camp4 Therapeutics Corp Chief Scientific Officer Daniel Tardiff received a grant of stock options covering 170,000 shares of common stock. The options have an exercise price of $4.46 per share and expire on March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, aligning compensation with long-term company performance. Following this award, Tardiff holds 170,000 stock options directly, reflecting a routine, compensation-related equity grant rather than an open-market trade.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Tardiff Daniel
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 170,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 170,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 170,000 options
Exercise price: $4.46 per share
Underlying shares: 170,000 shares
+3 more
6 metrics
Options granted
170,000 options
Stock Option (Right to Buy) grant to CSO
Exercise price
$4.46 per share
Conversion or exercise price of options
Underlying shares
170,000 shares
Common stock underlying the options
Expiration date
March 31, 2036
Option expiration date
Post-transaction options
170,000 options
Total options held following transaction
Vesting schedule
4 years, monthly
Equal monthly vesting from grant date
Key Terms
Stock Option (Right to Buy), exercise price, vest in equal monthly installments, Form 4
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 4.4600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in equal monthly installments financial
"shares underlying the option vest in equal monthly installments"
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did CAMP report for Daniel Tardiff on this Form 4?
Camp4 Therapeutics reported that Chief Scientific Officer Daniel Tardiff received a grant of stock options for 170,000 shares. These options are a compensation award, not an open‑market purchase or sale, and give him the right to buy CAMP common stock at a fixed exercise price.
How many CAMP stock options were granted to the Chief Scientific Officer?
Daniel Tardiff was granted stock options covering 170,000 shares of Camp4 Therapeutics common stock. This award represents his total option holdings reported after the transaction, indicating a new equity incentive position tied directly to the company’s future share performance over time.
What is the exercise price and expiration date of the CAMP options?
The stock options granted to Daniel Tardiff have an exercise price of $4.46 per share and expire on March 31, 2036. This means he can choose to buy CAMP shares at $4.46 any time before the 2036 expiration date, subject to vesting conditions being satisfied.
How do the CAMP options granted to Daniel Tardiff vest over time?
The options vest in equal monthly installments over four years starting from the grant date. This structure gradually delivers exercisable rights each month, encouraging long‑term alignment with Camp4 Therapeutics’ performance rather than providing immediate full ownership rights on the grant date.
Is this CAMP Form 4 transaction a stock purchase or sale on the market?
No, this Form 4 reports a grant of stock options as compensation, not an open‑market trade. Daniel Tardiff did not buy or sell shares in the market; he received the right to purchase CAMP shares later at a fixed exercise price if he chooses.